Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Aclaris Therapeutics reported a quarterly loss of $0.12 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of +7.69% [1] - The company generated revenues of $3.3 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 107.75%, although this is a decline from $4.35 million in the same quarter last year [2] - Aclaris shares have underperformed, losing about 8.9% since the beginning of the year, compared to a 15.6% gain in the S&P 500 [3] Financial Performance - Over the last four quarters, Aclaris has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $1.57 million, and for the current fiscal year, it is -$0.51 on revenues of $6.39 million [7] Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aclaris' stock performance [5][6]